|
Brain Neoplasms
|
0.500 |
CausalMutation
|
group |
CGI |
|
|
|
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
|
18985363 |
2008 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown.
|
19359588 |
2009 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We assessed IDH1 mutations in brain tumors diagnosed in patients from three families with Li-Fraumeni syndrome.
|
19340432 |
2009 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
|
19903171 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
20160062 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To address this, we analyzed IDH1(R132) and IDH2(R172) mutation status 53 metastatic brain tumors, including nine melanoma metastases.
|
20603105 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Another mitochondrial and TCA cycle-related protein, isocitrate dehydrogenase 2 is, together with IDH1, frequently mutated in the brain tumour glioblastoma.
|
20304625 |
2010 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acquired somatic mutations of IDH1 and IDH2 have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases.
|
22397365 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We investigated IDH1 mutations in a series of 134 brain tumors to determine the prevalence and prognostic impact of IDH1 mutations.
|
22922798 |
2012 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We also used targeted genotyping to examine the role of tumor-related genes in brain tumor development and specifically examined the clinical consequences of MAE at TP53 and IDH1.
|
22144470 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias.
|
22343896 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors.
|
22015945 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
|
23111198 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here, we describe the isolation of a glioma brain tumor stem cell line (BT142) with an endogenous R132H mutation in IDH1, aggressive tumor-initiating capacity, and 2-HG production.
|
22166263 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
|
22427879 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This study demonstrates the feasibility, specificity, and selectivity of using MR detection and quantification of 2HG for the diagnosis and classification of IDH1/2 mutation-positive brain tumors.
|
22426639 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
|
23558169 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Cytosolic isocitrate dehydrogenase 1 (IDH1) with an R132H mutation in brain tumors loses its enzymatic activity for catalyzing isocitrate to α-ketoglutarate (α-KG) and acquires new activity whereby it converts α-KG to 2-hydroxyglutarate.
|
24077277 |
2013 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
There is growing interest in identification of diagnostic, prognostic or predictive blood biomarkers in CNS tumor patients, and emerging studies indicate that certain brain tumors are indeed associated with distinct profiles of circulating factors such as proteins (e.g., glial fibrillary acidic protein), DNA fragments (e.g., containing mutated IDH) or miRNAs (e.g., miRNA-21).
|
23547822 |
2013 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such as BRAF, RAS and IDH1 in colon and brain tumours.
|
23414134 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH mutation screening is rapidly becoming part of the routine pathological work up of human brain tumors, providing both diagnostic and prognostic information.
|
23307057 |
2013 |
|
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used human glioma tissues and derived brain tumor stem cells (BTSCs) to study the expression of HIF1α target genes in IDH mutant ((mt)) and IDH wild-type ((wt)) tumors.
|
24366912 |
2014 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal lobe.
|
25225364 |
2014 |